表紙
市場調査レポート

ドライアイ症候群(DES)- 現在/将来の市場参入企業

Dry Eye Syndrome - Current and Future Players

発行 GlobalData 商品コード 281777
出版日 ページ情報 英文 84 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
ドライアイ症候群(DES)- 現在/将来の市場参入企業 Dry Eye Syndrome - Current and Future Players
出版日: 2015年11月05日 ページ情報: 英文 84 Pages
概要

当レポートでは、ドライアイ症候群(DES)治療薬について調査分析し、現在/将来の市場参入企業の現状と促進要因に焦点を当てて、競合分析、企業プロファイルなどを提供しております。

第1章 目次

第2章 イントロダクション

第3章 市場見通し

  • 世界市場
    • 予測
    • 促進要因・障壁

第4章 現在/将来の市場参入企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Alcon
    • Allergan
    • Herantis
    • Mimetogen
    • Mitotech
    • 大塚ホールディングス
    • RegeneRx
    • 参天製薬
    • Shire/SARcode Bioscience

第5章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1049FPR

GlobalData has released its pharma report, "Dry Eye Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Dry Eye Syndrome Market. The report identifies and analyses the key companies shaping and driving the global Dry Eye Syndrome market. The report provides insight into the competitive Dry Eye Syndrome landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Dry Eye Syndrome
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Dry Eye Syndrome sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Dry Eye Syndrome market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Dry Eye Syndrome market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Alcon
    • 4.3.2. Allergan
    • 4.3.3. Herantis
    • 4.3.4. Mimetogen
    • 4.3.5. Mitotech
    • 4.3.6. Otsuka
    • 4.3.7. RegeneRx
    • 4.3.8. Santen
    • 4.3.9. Shire

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed DES Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. Launch Dates
    • 5.4.4. General Pricing Assumptions
    • 5.4.5. Individual Drug Assumptions
    • 5.4.6. Pricing of Pipeline Agents
  • 5.5. Primary Research - KOLs Interviewed for this Report
  • 5.6. Primary Research - High-prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Area Director
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 2: DES Market - Drivers and Barriers, 2014-2024
  • Table 3: Key Companies in the Dry Eye Syndrome Market in the 9MM, 2014
  • Table 4: Allergan's DES Portfolio Assessment, 2015
  • Table 5: Herantis's DES Portfolio Assessment, 2015
  • Table 6: Mimetogen's DES Portfolio Assessment, 2015
  • Table 7: Mitotech's DES Portfolio Assessment, 2015
  • Table 8: Otsuka's DES Portfolio Assessment, 2015
  • Table 9: RegeneRx's DES Portfolio Assessment, 2015
  • Table 10: Santen's DES Portfolio Assessment, 2015
  • Table 11: Shire's DES Portfolio Assessment, 2015
  • Table 12: Key Launch Dates
  • Table 13: Surveyed High-prescribing Physicians, by Country

List of Figures

  • Figure 1: Global Sales for DES Therapies by Region, 2014 and 2024
  • Figure 2: Global Sales by Region for DES Therapies, 2014-2024
  • Figure 3: Global Sales for DES by Drug, 2014 and 2024
  • Figure 4: Global Sales by Drug for DES Therapies, 2014-2024
  • Figure 5: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2014-2024
Back to Top